A quantitative systems pharmacology (QSP) model for Pneumocystis treatment in mice

BackgroundThe yeast-like fungi Pneumocystis, resides in lung alveoli and can cause a lethal infection known as Pneumocystis pneumonia (PCP) in hosts with impaired immune systems. Current therapies for PCP, such as trimethoprim-sulfamethoxazole (TMP-SMX), suffer from significant treatment failures and a multitude of serious side effects. Novel therapeutic approaches (i.e. newly developed drugs or novel combinations of available drugs) are needed to treat this potentially lethal opportunistic infection. Quantitative Systems Pharmacological (QSP) models promise to aid in the development of novel therapies by integrating available pharmacokinetic (PK) and pharmacodynamic (PD) knowledge to predict the effects of new treatment regimens.ResultsIn this work, we constructed and independently validated PK modules of a number of drugs with available pharmacokinetic data. Characterized by simple structures and well constrained parameters, these PK modules could serve as a convenient tool to summarize and predict pharmacokinetic profiles. With the currently accepted hypotheses on the life stages of Pneumocystis, we also constructed a PD module to describe the proliferation, transformation, and death of Pneumocystis. By integrating the PK module and the PD module, the QSP model was constrained with observed levels of asci and trophic forms following treatments with multiple drugs. Furthermore, the temporal dynamics of the QSP model were validated with corresponding data.ConclusionsWe developed and validated a QSP model that integrates available data and promises to facilitate the design of future therapies against PCP.

[1]  Hui Qu,et al.  Risk factors for mortality from pneumocystis carinii pneumonia (PCP) in non-HIV patients: a meta-analysis , 2017, Oncotarget.

[2]  Francisco Antunes,et al.  Therapeutic Potential of Caspofungin Combined with Trimethoprim-Sulfamethoxazole for Pneumocystis Pneumonia: A Pilot Study in Mice , 2013, PloS one.

[3]  F. Schluenzen,et al.  Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria , 2001, Nature.

[4]  Melanie T. Cushion,et al.  Echinocandin Treatment of Pneumocystis Pneumonia in Rodent Models Depletes Cysts Leaving Trophic Burdens That Cannot Transmit the Infection , 2010, PloS one.

[5]  Jacques Bille,et al.  Association between a specific Pneumocystis jiroveci dihydropteroate synthase mutation and failure of pyrimethamine/sulfadoxine prophylaxis in human immunodeficiency virus-positive and -negative patients. , 2003, The Journal of infectious diseases.

[6]  Jacques Bille,et al.  Pneumocystis jirovecii Dihydrofolate Reductase Polymorphisms Associated with Failure of Prophylaxis , 2003, The Journal of eukaryotic microbiology.

[7]  Marco Pagni,et al.  Identification and Functional Ascertainment of the Pneumocystis jirovecii Potential Drug Targets Gsc1 and Kre6 Involved in Glucan Synthesis , 2017, The Journal of eukaryotic microbiology.

[8]  Adithya Cattamanchi,et al.  HIV-associated Pneumocystis pneumonia. , 2011, Proceedings of the American Thoracic Society.

[9]  Raoul Herbrecht,et al.  Caspofungin: the first representative of a new antifungal class. , 2003, The Journal of antimicrobial chemotherapy.

[10]  M. Pfaller,et al.  In Vivo Pharmacodynamic Characterization of Anidulafungin in a Neutropenic Murine Candidiasis Model , 2007, Antimicrobial Agents and Chemotherapy.

[11]  Tarek A. Leil,et al.  Quantitative Systems Pharmacology can reduce attrition and improve productivity in pharmaceutical research and development , 2014, Front. Pharmacol..

[12]  I. Macreadie,et al.  Isolation of the Pneumocystis carinii dihydrofolate synthase gene and functional complementation in Saccharomyces cerevisiae. , 2006, FEMS microbiology letters.

[13]  Tarek A. Leil,et al.  Editorial: The emerging discipline of quantitative systems pharmacology , 2015, Front. Pharmacol..

[14]  J. Castro,et al.  Management of Pneumocystis Jirovecii pneumonia in HIV infected patients: current options, challenges and future directions. , 2010, HIV/AIDS.

[15]  Naimish Patel,et al.  Pneumocystis jiroveci Pneumonia in Adult Patients with AIDS , 2004, Treatments in respiratory medicine.

[16]  Paul G. Ambrose,et al.  Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters , 2017, Antimicrobial Agents and Chemotherapy.

[17]  A. Sinai,et al.  The 12th International Workshops on Opportunistic Protists (IWOP‐12) , 2013, The Journal of eukaryotic microbiology.

[18]  George L. Drusano,et al.  Anidulafungin Pharmacokinetics and Microbial Response in Neutropenic Mice with Disseminated Candidiasis , 2006, Antimicrobial Agents and Chemotherapy.

[19]  W. Foye,et al.  Foye's Principles of Medicinal Chemistry , 2002 .

[20]  Ola Sköld,et al.  Sulfonamide resistance: mechanisms and trends. , 2000, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[21]  R J Artymowicz,et al.  Atovaquone: a new antipneumocystis agent. , 1993, Clinical pharmacy.

[22]  Dennis Schmatz,et al.  Efficacy of MK-991 (L-743,872), a Semisynthetic Pneumocandin, in Murine Models ofPneumocystis carinii , 1998, Antimicrobial Agents and Chemotherapy.

[23]  Ulrika S H Simonsson,et al.  A multistate tuberculosis pharmacometric model: a framework for studying anti-tubercular drug effects in vitro , 2015, The Journal of antimicrobial chemotherapy.

[24]  Patrick Taffé,et al.  Pneumocystis jirovecii Genotype Associated with Increased Death Rate of HIV-infected Patients with Pneumonia , 2013, Emerging infectious diseases.

[25]  Andrew H. Limper,et al.  Evidence for a Melanin Cell Wall Component in Pneumocystis carinii , 2003, Infection and Immunity.

[26]  Melanie T. Cushion,et al.  Pneumocystis Workshop: 10th Anniversary Summary , 2009, Eukaryotic Cell.

[27]  Oleg Demin,et al.  Integration not isolation: arguing the case for quantitative and systems pharmacology in drug discovery and development. , 2011, Drug discovery today.

[28]  L. Weiss,et al.  The 13th International Workshops on Opportunistic Protists (IWOP13) , 2015, The Journal of eukaryotic microbiology.

[29]  M. Pfaller,et al.  In Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida Species , 2010, Antimicrobial Agents and Chemotherapy.

[30]  M. Cushion,et al.  In Vitro Selection and In Vivo Efficacy of Piperazine- and Alkanediamide-Linked Bisbenzamidines against Pneumocystis Pneumonia in Mice , 2006, Antimicrobial Agents and Chemotherapy.

[31]  Jacques Bille,et al.  Mutations of Pneumocystis jirovecii Dihydrofolate Reductase Associated with Failure of Prophylaxis , 2004, Antimicrobial Agents and Chemotherapy.

[32]  Brad Reisfeld,et al.  A Physiologically Based Pharmacokinetic Model of Rifampin in Mice , 2013, Antimicrobial Agents and Chemotherapy.

[33]  Kristina Crothers,et al.  Dihydropteroate Synthase Gene Mutations in Pneumocystis and Sulfa Resistance , 2004, Emerging infectious diseases.

[34]  F Leitner,et al.  Antibacterial activity of phosphanilic acid, alone and in combination with trimethoprim , 1985, Antimicrobial Agents and Chemotherapy.

[35]  Yaning Wang,et al.  Leveraging Prior Quantitative Knowledge to Guide Drug Development Decisions and Regulatory Science Recommendations: Impact of FDA Pharmacometrics During 2004–2006 , 2008, Journal of clinical pharmacology.

[36]  Michael A. Lyons,et al.  Computational pharmacokinetics/pharmacodynamics of rifampin in a mouse tuberculosis infection model , 2015, Journal of Pharmacokinetics and Pharmacodynamics.

[37]  Michael A. Lyons,et al.  Computational pharmacology of rifampin in mice: an application to dose optimization with conflicting objectives in tuberculosis treatment , 2014, Journal of Pharmacokinetics and Pharmacodynamics.

[38]  Mark G Thomas,et al.  Good outcome with trimethoprim 10 mg/kg/day-sulfamethoxazole 50 mg/kg/day for Pneumocystis jirovecii pneumonia in HIV infected patients , 2009, Scandinavian journal of infectious diseases.

[39]  Hsin-Yun Sun,et al.  Treatment of Pneumocystis jirovecii pneumonia in HIV-infected patients: a review , 2017, Expert review of anti-infective therapy.

[40]  V. Chelliah,et al.  The promises of quantitative systems pharmacology modelling for drug development , 2016, Computational and structural biotechnology journal.

[41]  Andrew J Copas,et al.  Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[42]  Ana Espinel-Ingroff,et al.  Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). , 2009, Revista iberoamericana de micologia.

[43]  MC Peterson,et al.  FDA Advisory Meeting Clinical Pharmacology Review Utilizes a Quantitative Systems Pharmacology (QSP) Model: A Watershed Moment? , 2015, CPT: pharmacometrics & systems pharmacology.

[44]  H Kropp,et al.  Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872) , 1997, Antimicrobial agents and chemotherapy.